Xarelto provides effective protection from stroke in patients with atrial fibrillation and co-

morbidities

Patients with atrial fibrillation (AF) are at a high risk for stroke, and the prevalence of AF
increases with age1

Patients with AF are likely to have co-morbid conditions2

Cardiovascular disease often coincides with AF because of overlapping risk

factors

Coronary artery disease occurs in 20%40% of patients with AF3,4

Renal impairment increases stroke risk in patients with AF5

Guidelines recommend that patients with non-valvular AF (NVAF) are treated with
non-vitamin K antagonist oral anticoagulants to reduce stroke risk1

Co-morbidities should be considered when managing patients with AF

Subgroup analyses of the phase III ROCKET AF study demonstrated the efficacy and
safety of rivaroxaban 20 mg once daily (od) versus warfarin for stroke prevention in 14,264
patients with AF and co-morbidities6

Of those patients with moderate renal impairment (creatinine clearance 3049

ml/min), 20.7% received rivaroxaban 15 mg od or warfarin, and treatment efficacy was
consistent with that of full-dose anticoagulation5

Rivaroxaban was effective in patients aged 75 years (44% of the population)

and had a good safety profile, although the overall risk of stroke and bleeding was higher
compared with younger patients7

The presence of prior stroke (52% of patients) did not impact the efficacy of
rivaroxaban treatment8

The PIONEER AF-PCI trial demonstrated that rivaroxaban plus antiplatelet

therapy had a better safety profile than vitamin K antagonist plus dual antiplatelet therapy in
patients with AF undergoing percutaneous coronary intervention (PCI) with stenting9